Compare PCRX & ADTN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PCRX | ADTN |
|---|---|---|
| Founded | 2006 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Telecommunications Equipment |
| Sector | Health Care | Telecommunications |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2010 | 1996 |
| Metric | PCRX | ADTN |
|---|---|---|
| Price | $23.58 | $15.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | ★ $30.25 | $15.50 |
| AVG Volume (30 Days) | 513.2K | ★ 2.7M |
| Earning Date | 04-30-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 107.44 | 90.83 |
| EPS | ★ 0.07 | N/A |
| Revenue | $541,533,000.00 | ★ $1,083,807,000.00 |
| Revenue This Year | $6.78 | $11.09 |
| Revenue Next Year | $8.54 | $8.47 |
| P/E Ratio | $330.36 | ★ N/A |
| Revenue Growth | ★ 26.04 | 17.46 |
| 52 Week Low | $18.80 | $7.11 |
| 52 Week High | $27.64 | $18.69 |
| Indicator | PCRX | ADTN |
|---|---|---|
| Relative Strength Index (RSI) | 47.26 | 48.99 |
| Support Level | $20.15 | $8.39 |
| Resistance Level | $24.20 | $18.34 |
| Average True Range (ATR) | 1.28 | 0.94 |
| MACD | -0.25 | -0.35 |
| Stochastic Oscillator | 25.08 | 23.23 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Adtran Holdings Inc is a provider of networking and communications platforms, software, and services focused on the broadband access market. It operates under two reportable segments: Network Solutions segment, which includes hardware and software products that enable a digital future that supports the company's Subscriber, Access & Aggregation, and Optical Networking Solutions; and Services & Support segment, which includes network design, implementation, maintenance and cloud-hosted services supporting the company's Subscriber, Access & Aggregation, and Optical Networking Solutions. It generates the majority of its revenue from the Network Solutions segment.